Evidence map›Paper›PMID 29662293›Full record

Trial reportWorld journal of gastroenterology2018

Maintenance for healed erosive esophagitis: Phase III comparison of vonoprazan with lansoprazole.

Kiyoshi Ashida, Katsuhiko Iwakiri, Naoki Hiramatsu, Yuuichi Sakurai, Tetsuharu Hori, Kentarou Kudou, Akira Nishimura, Eiji Umegaki

Open access · hybridAbstract readClinical Trial, Phase IIIEquivalence TrialRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in World journal of gastroenterology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
60citing papers in PubMed, 7 pooled it
4.3field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

60 citing papers in PubMed, 7 syntheses or guidelines pooled it, 105 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Guideline
  7. Pooled it
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Kiyoshi AshidaDepartment of Gastroenterology, Rakuwakai Otowa Hospital, Kyoto 607-8062, Japan. rakuwadr1185@rakuwadr.com.
Katsuhiko IwakiriDepartment of Gastroenterology, Nippon Medical School Graduate School of Medicine, Tokyo 113-8603, Japan.
Naoki HiramatsuDepartment of Gastroenterology and Hepatology, Osaka Rosai Hospital, Sakai, Osaka 591-8025, Japan.
Yuuichi SakuraiTakeda Pharmaceutical Company Limited, Osaka 540-8645, Japan.
Tetsuharu HoriTakeda Pharmaceutical Company Limited, Osaka 540-8645, Japan.
Kentarou KudouTakeda Pharmaceutical Company Limited, Osaka 540-8645, Japan.
Akira NishimuraTakeda Pharmaceutical Company Limited, Osaka 540-8645, Japan.
Eiji UmegakiDepartment of Gastroenterology, Kobe University Graduate School of Medicine, Kobe, Hyogo 650-0017, Japan.
Osaka Rosai Hospital · JPTakeda (Japan) · JPNippon Medical School · JPRakuwakai Otowa Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimTo compare vonoprazan 10 and 20 mg

methodsA total of 607 patients aged ≥ 20 years, with endoscopically-confirmed healed EE following 8 wk of treatment with vonoprazan 20 mg once daily, were randomized 1:1:1 to receive lansoprazole 15 mg (

resultsRates of EE recurrence during the 24-wk maintenance period were 16.8%, 5.1%, and 2.0% with lansoprazole 15 mg, vonoprazan 10 mg, and vonoprazan 20 mg, respectively. Vonoprazan was shown to be non-inferior to lansoprazole 15 mg (

conclusionOur findings confirm the non-inferiority of vonoprazan 10 and 20 mg to lansoprazole 15 mg as maintenance therapy for patients with healed EE.

Indexed as

AdultAgedBiopsyDouble-Blind MethodEsophagitis, PepticEsophagoscopyEsophagusFemaleGastric MucosaGastroesophageal RefluxHeartburnHumansIncidenceLansoprazoleMaleMiddle Aged1-(5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl)-N-methylmethanamineLansoprazoleProton Pump InhibitorsPyrrolesSulfonamidesErosive esophagitisGastroesophageal reflux diseaseLansoprazoleMaintenance therapyPotassium-competitive acid blockersVonoprazan

Identifiers

PMID29662293
PMCPMC5897859
OpenAlexW2797397035

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.